Information  X 
Enter a valid email address

EPIC/TIDM matching '68CT'

Date
Time Source
Company
Announcement
29 Jul 2019 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
18 Jul 2019 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
01 Jul 2019 4:30 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
07 Jun 2019 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces new leader of Pharmaceuticals Business Unit
26 May 2019 11:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24 May 2019 5:41 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
  5:32 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
08 May 2019 11:20 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
24 Apr 2019 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
26 Mar 2019 11:35 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22 Mar 2019 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis plans for Alcon spin-off on April 9, 2019
14 Mar 2019 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces change in Sandoz leadership
25 Feb 2019 10:55 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
30 Jan 2019 3:17 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
21 Dec 2018 1:53 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis successfully completes acquisition of Endocyte
20 Dec 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces new CEO of Oncology Business Unit
13 Nov 2018 9:29 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
18 Oct 2018 6:02 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
29 Aug 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
23 Aug 2018 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14 Aug 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
27 Jul 2018 1:53 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
18 Jul 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29 Jun 2018 1:10 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
01 Jun 2018 1:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
  12:40 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
18 May 2018 12:14 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
16 May 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces changes to the Executive Committee
01 May 2018 9:26 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis provides update on proposed acquisition of AveXis
19 Apr 2018 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered a strong first quarter and acted to become a more focused medicines company
17 Apr 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis tender offer for AveXis commences
09 Apr 2018 5:45 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
27 Mar 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
01 Feb 2018 9:05 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
26 Jan 2018 6:02 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24 Jan 2018 6:02 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
11 Jan 2018 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis appoints Elizabeth Barrett as Oncology Head
15 Dec 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces Oncology head to retire
13 Nov 2017 5:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
  2:51 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
30 Oct 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
24 Oct 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered growth on top and bottom line in all divisions in Q3
04 Sep 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30 Aug 2017 4:04 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28 Aug 2017 8:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
  8:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
18 Jul 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
12 Jul 2017 10:24 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
22 Jun 2017 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
20 Jun 2017 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
31 May 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t